1. Home
  2. CION vs ABEO Comparison

CION vs ABEO Comparison

Compare CION & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CION Investment Corporation

CION

CION Investment Corporation

SELL

Current Price

$6.01

Market Cap

324.2M

Sector

Finance

ML Signal

SELL

Logo Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc.

HOLD

Current Price

$2.61

Market Cap

282.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CION
ABEO
Founded
2011
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.2M
282.5M
IPO Year
2011
2005

Fundamental Metrics

Financial Performance
Metric
CION
ABEO
Price
$6.01
$2.61
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$8.75
★ $15.56
AVG Volume (30 Days)
424.3K
★ 2.1M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 19.70%
N/A
EPS Growth
N/A
★ 165.16
EPS
★ N/A
N/A
Revenue
N/A
★ $2,998,000.00
Revenue This Year
N/A
$675.42
Revenue Next Year
N/A
$126.99
P/E Ratio
$17.55
★ N/A
Revenue Growth
N/A
★ 258.18
52 Week Low
$5.83
$2.09
52 Week High
$10.40
$7.65

Technical Indicators

Market Signals
Indicator
CION
ABEO
Relative Strength Index (RSI) 35.12 25.77
Support Level $5.90 N/A
Resistance Level $7.25 $5.77
Average True Range (ATR) 0.23 0.33
MACD -0.06 -0.15
Stochastic Oscillator 12.40 18.75

Price Performance

Historical Comparison
CION
ABEO

About CION CION Investment Corporation

CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Share on Social Networks: